Prime Medicine (NASDAQ:PRME) Shares Gap Up Following Better-Than-Expected Earnings

Key Points

• Prime Medicine shares jumped after the company reported a quarterly loss of $0.22 per share, beating analyst expectations of a $0.23 loss; quarterly revenue was $4.21 million.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $7.86, with recent targets including $7 and $8.
• The company remains unprofitable, reporting a negative return on equity of 188.27% and a net margin of -4,613.11%; it has no approved therapies on the market.

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s share price gapped up before the market opened on Friday following a better than expected earnings announcement. The stock had previously closed at $3.89, but opened at $4.05. Prime Medicine shares last traded at $4.2340, with a volume of 648,466 shares traded.

The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. The company had revenue of $4.21 million during the quarter. Prime Medicine had a negative return on equity of 188.27% and a negative net margin of 4,613.11%.

Analysts Set New Price Targets

PRME has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Prime Medicine in a research report on Monday, August 10th. Chardan Capital reissued a "buy" rating and issued a $7.00 price target on shares of Prime Medicine in a research report on Friday, September 25th. Wall Street Zen upgraded shares of Prime Medicine from a "sell" rating to a "hold" rating in a research note on Saturday, October 31st. Jefferies Financial Group reaffirmed a "market outperform" rating on shares of Prime Medicine in a report on Monday, September 28th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Prime Medicine in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $7.86.

Institutional Investors Weigh In On Prime Medicine

Hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Prime Medicine during the third quarter valued at approximately $28,000. Royal Bank of Canada lifted its position in Prime Medicine by 89.3% in the first quarter. Royal Bank of Canada now owns 9,254 shares of the company's stock worth $32,000 after purchasing an additional 4,365 shares during the period. Wealthfront Advisers LLC bought a new position in Prime Medicine in the first quarter worth $36,000. Kingsview Wealth Management LLC acquired a new stake in Prime Medicine during the second quarter worth $37,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in Prime Medicine during the first quarter worth $41,000. Institutional investors own 70.37% of the company's stock.

Prime Medicine Price Performance

The stock has a market cap of $759.62 million, a price-to-earnings ratio of -3.97 and a beta of 2.14. The stock's 50 day simple moving average is $3.69 and its two-hundred day simple moving average is $3.51.

About Prime Medicine

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.